Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Berry, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2003; 96: 873-874
© 2003 Association of Physicians

Biologic

Misplaced

Colin Berry

The first 10% of the full text of this article appears below.

In a recent trial of gene therapy for an immunodeficiency state (X-linked severe combined immunodeficiency disorder), two of eleven children developed leukaemia. The haematopoetic stem cells of the patents, from the bone marrow, had been transduced with a vector based on an onco-retrovirus, the murine leukaemia virus (MLV). The vector expressed the common gamma chain of the interleukin receptor. In the two leukaemic children, the leukaemic clone contained vector DNA that had integrated in the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?